版本:
中国

BRIEF-Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

June 1 Roche Holding AG

* Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

* ‍Ventana ALK CDX assay identifies ALK-positive NSCLC patients eligible for treatment with novartis drug zykadia, expanding current treatment options​

* ‍Ventana ALK (D5F3) CDX assay is available for use on benchmark IHC/ISH instruments​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐